(Q34164663)

31 July 2017

1 reference

title

Bispecific human IgG by design (English)

1 reference

31 July 2017

Carter P

1

1 reference

31 July 2017

publication date

1 February 2001

1 reference

Journal of Immunological Methods

31 July 2017

published in

1 reference

31 July 2017

volume

248

1 reference

31 July 2017

issue

1-2

1 reference

31 July 2017

page(s)

7-15

1 reference

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Bispecific antibodies as novel bioconjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

High level Escherichia coli expression and production of a bivalent humanized antibody fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Toward the production of bispecific antibody fragments for clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Bispecific receptor globulins, novel tools for the study of cellular interactions. Preparation and characterization of an E-selectin/P-selectin bispecific receptor globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

"Diabodies": small bivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Retargeting serum immunoglobulin with bispecific diabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Recombinant antibody constructs in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Humanised monoclonal antibody therapy for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Complement recruitment using bispecific diabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

An efficient route to human bispecific IgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Protein-protein recognition and the association of immunoglobulin constant domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Hybrid hybridomas and their use in immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

A dimeric bispecific miniantibody combines two specificities with avidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Tetravalent miniantibodies with high avidity assembling in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

New protein engineering approaches to multivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Bispecific antibodies in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Bispecific monoclonal antibodies from hybrid hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Human antibodies by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

Remodeling domain interfaces to enhance heterodimer formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

High level secretion of a humanized bispecific diabody from Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900339-2

10.1016/S0022-1759(00)00339-2

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference